ArticleScientific reports2026
Integrative machine learning and multi-omics analysis reveals ATIC as a promoter of hepatocellular carcinoma progression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Autophagy plays a non-negligible role in the progression and immune regulation of hepatocellular carcinoma (HCC). An integrated analysis of the autophagy-related genes (ARGs) is of significance to deepen our mechanistic understanding about HCC pathology. In our present work, based on the expression patterns of 221 ARGs, we first identified 2 autophagy-related subtypes for TCGA-HCC patients using consensus clustering method. The two subtypes showed considerable distinctions in terms of molecular characteristics, immune landscapes and clinical outcomes. To augment the clinical utility of the subtyping system, a four-gene prognostic model including ATIC, RHEB, TMEM74 and PRKCD was developed and verified through LASSO and multivariate Cox regression analyses. ROC(AUC) analysis confirmed the predictive efficacy of the model across the training and validation cohorts. Notably, HCC patients in the high-risk group exhibited elevated tumor mutation burdens and higher expression of multiple immune checkpoint genes, suggesting distinct immune-related features between risk groups. Furthermore, single-cell RNA sequencing analysis revealed that the model's marker gene-ATIC was predominantly expressed in tumor cells and proliferative T cells, with its expression showing strong and positive associations with autophagy activity. Finally, in vitro experiments were conducted to explore the potential role of ATIC in HCC. The results indicated that ATIC knockdown was associated with reduced proliferative and migratory capacities of HCC cells, along with alterations in autophagy-related phenotypes, including decreased autophagic flux. Taken together, our study provides a preliminary autophagy-related prognostic signature and identifies ATIC as a potential regulator of HCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.